Cridanimod

A synthetic immunomodulator used in cancer treatment

Cridanimod
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Cridanimod is a synthetic immunomodulatory agent that has been investigated for its potential use in the treatment of certain types of cancer, particularly endometrial cancer. It is known to enhance the activity of progesterone receptors, thereby potentially increasing the effectiveness of progestin therapy in hormone-sensitive tumors.

Mechanism of Action

Cridanimod functions primarily as an immunomodulator. It is believed to work by inducing the production of interferons, which are proteins that play a crucial role in the immune response against tumors. By increasing the levels of interferons, cridanimod may enhance the body's natural ability to fight cancer cells. Additionally, cridanimod has been shown to upregulate the expression of progesterone receptors in cancer cells, which can make these cells more responsive to hormone-based therapies.

Clinical Applications

Cridanimod has been studied in the context of endometrial cancer, where it is used in combination with progestin therapy. The rationale for this combination is that cridanimod can increase the expression of progesterone receptors, thereby enhancing the effectiveness of progestins in inhibiting tumor growth. Clinical trials have been conducted to evaluate the safety and efficacy of cridanimod in this setting, with some studies suggesting a potential benefit in terms of tumor response and progression-free survival.

Pharmacokinetics

The pharmacokinetic profile of cridanimod involves its absorption, distribution, metabolism, and excretion in the body. After administration, cridanimod is absorbed and distributed throughout the body, where it exerts its immunomodulatory effects. The metabolism of cridanimod and its excretion pathways are subjects of ongoing research, as understanding these processes is crucial for optimizing its use in clinical settings.

Side Effects

As with many immunomodulatory agents, cridanimod may cause a range of side effects. Commonly reported adverse effects include flu-like symptoms, such as fever, fatigue, and muscle aches, which are associated with increased interferon levels. Other potential side effects include gastrointestinal disturbances and injection site reactions. The safety profile of cridanimod is an important consideration in its clinical use, and ongoing studies aim to better characterize these effects.

Research and Development

Research into cridanimod is ongoing, with studies focusing on its potential applications in various types of cancer beyond endometrial cancer. Investigators are exploring its use in combination with other therapeutic agents, as well as its role in enhancing the immune response to tumors. The development of cridanimod is part of a broader effort to harness the immune system in the fight against cancer, a field known as immuno-oncology.

Related Pages

• Endometrial cancer
• Progesterone receptor
• Immunomodulator
• Interferon
• Progestin